Company / Total Assets
ADMA Biologics, Inc. Total Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$624.2M
FY2025
5-year range
$276.3M / $624.2M
FY2021-FY2025
Trend
+27.7%
vs FY2024
Sector context
#119 of 214
Health Care
What the data says
At $624M, ADMA Biologics, Inc.'s total assets ranks #119 of 214 in the Health Care sector. Total Assets has increased for 3 consecutive years, from $276M in FY2022 to $624M in FY2025.
Based on SEC 10-K filings.
$624M in FY2025 with a 5-year CAGR of +24.6%.
Improved from $329M to $624M over the past 2 years.
Health Care sector context is included.
Total Assets over time
Growth rates
- 3-Year CAGR
- +31.2%
- 5-Year CAGR
- +24.6%
- 10-Year CAGR
- -
Sector benchmark
#119 of 214 in Health CareTop 56% of 214This company $624.2M Sector average $7.5B
▼
-91.6% below sector average
Key checks
Key Insights
- ADMA Biologics, Inc.'s total assets has grown for 3 consecutive years.
- 5-year CAGR of +24.6%, indicating consistent growth.
- In FY2025, total assets increased 27.7% year-over-year.
- Ranks #119 out of 214 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.37 (safe zone, above 2.9 threshold)
- Strong profit margin: 46.4%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $624.2M | +27.7% |
| FY2024 | $488.7M | +48.5% |
| FY2023 | $329.2M | +19.2% |
| FY2022 | $276.3M | -0.0% |
| FY2021 | $276.3M | +33.0% |
| FY2020 | $207.7M | +63.4% |
| FY2019 | $127.1M | +43.0% |
| FY2018 | $88.9M | -17.7% |
| FY2017 | $108.0M | +356.1% |
| FY2016 | $23.7M | -0.1% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026